Caprihans India Limited received official SEBI (SAST) regulatory disclosure from promoter Bilcare Limited regarding the fourth tranche warrant conversion completed on March 25, 2026. The comprehensive filing under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 confirms the conversion of 3.30 lakh warrants into equity shares, increasing Bilcare Limited's shareholding to 59.56%.

Official SEBI SAST Regulatory Disclosure

Bilcare Limited submitted detailed disclosure documentation to BSE Limited and Caprihans India Limited, confirming the exercise of warrant conversion rights during the fourth tranche of the financial year 2025-26. Company Secretary Sagar R. Baheti executed the mandatory filing with comprehensive details of the preferential allotment pursuant to convertible warrant conversion.

Progressive Shareholding Pattern Analysis

The regulatory disclosure provides comprehensive details of all four warrant conversion tranches executed during financial year 2025-26. Bilcare Limited's systematic conversion pattern demonstrates consistent exercise of warrant rights, with shareholding progression from 55.99% to 59.56% across the conversion period.

Current Shareholding Structure

Following the latest warrant conversion, Bilcare Limited's equity shareholding increased from 91.48 lakh shares to 94.78 lakh shares, representing 59.56% of the total paid-up equity share capital. The disclosure confirms the company's position as sole promoter with significant remaining warrant holdings for potential future conversions.

Capital Structure Impact Assessment

The regulatory filing details the equity share capital increase from ₹15.58 crores to ₹15.91 crores following the warrant conversion. The disclosure includes comprehensive diluted share capital calculations assuming full conversion of the remaining 20.20 lakh warrants, projecting total diluted capital of ₹17.93 crores.

Regulatory Compliance Framework

The comprehensive disclosure demonstrates full compliance with SEBI (SAST) Regulations, 2011, including detailed acquisition particulars, mode of acquisition through preferential allotment, and post-conversion shareholding patterns. The filing confirms the transaction execution in accordance with applicable provisions of the Companies Act, 2013 and SEBI regulations.

Caprihans India Limited announced its Q3FY26 financial results through a board meeting outcome dated February 10, 2026, reporting continued losses amid challenging market conditions. The pharma packaging solutions company posted a net loss of ₹15.96 crores, showing improvement from the ₹18.51 crores loss recorded in the corresponding quarter of the previous year.

Financial Performance Overview

The company's standalone financial results revealed mixed performance indicators for Q3FY26. While the net loss narrowed compared to the previous year, revenue from operations declined significantly.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Caprihans India showed improved performance compared to the previous year. The company reported a net loss of ₹54.48 crores against ₹64.50 crores in the corresponding period of FY25.

Consolidated Financial Performance

The consolidated results, which include subsidiary Bilcare Research GmbH, showed similar trends with a net loss of ₹15.60 crores for Q3FY26 compared to ₹18.56 crores in the previous year.

Corporate Restructuring and Leadership Changes

The company's Board of Directors approved several significant corporate actions during their meeting held on February 10, 2026. The most notable decision involved the redemption of 2,80,50,000 preference shares valued at ₹28.05 crores, reducing the total outstanding preference shares from 16,66,50,000 to 13,86,00,000 shares.

In terms of leadership transitions, Mr. Guman Mal Jain resigned from his position as Chief Financial Officer effective February 10, 2026, citing personal reasons. The Board appointed Mr. Pritam Paul as the new CFO effective February 11, 2026, in addition to his existing role as Business Head – Flexible PVC.

Board Composition Enhancement

The company strengthened its board composition with the appointment of Mr. Sanjeev D. Tole as Additional Independent Director effective February 10, 2026. Mr. Tole brings over 50 years of experience in corporate governance, Company Law, and regulatory compliances, having served in senior positions across various organizations.

Exceptional Items Impact

The company recorded exceptional expenses of ₹1.72 crores in Q3FY26, primarily related to the impact of new Labour Codes notified by the Government of India in November 2025. These codes consolidated 29 existing labour laws and resulted in incremental gratuity provisions due to changes in wage definitions.

Operational Highlights

Caprihans India continues to focus on its core business of pharma packaging solutions, operating as a single reportable segment. The company maintains its registered office at Shiroli, Rajgurunagar, Pune, and operates with a paid-up equity share capital of ₹14.62 crores as of December 31, 2025. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors providing their limited review report on the unaudited financial statements.